News | August 09, 2022
Briefs: Zydus Lifesciences and Kimia Biosciences
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
New Director supports NASDAQ rule on diversity
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
The life sciences and pharmaceutical sectors suffer from hard-to-source biological materials, which translates into high costs in research and development
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Subscribe To Our Newsletter & Stay Updated
